StockNews.AI
XNCR
StockNews.AI
173 days

Xencor Reports Fourth Quarter and Full Year 2024 Financial Results

1. Xencor reports financial results and pipeline updates for 2024. 2. Focus on XmAb® candidates aims to optimize therapeutic potential.

Earnings
+7.93%Current Return
VS
-1.13%S&P 500
$14.3802/27 08:14 AM EDTEvent Start
$15.5202/28 02:55 PM EDTLatest Updated
2m saved
Insight
Article

FAQ

Why Bullish?

Xencor's focus on XmAb® candidates signals potential for increased efficacy and market interest, similar to past successes in their drug development pipeline.

How important is it?

The strategic shift towards XmAb® candidates suggests a potential transformational impact on growth, likely driving investor confidence and market valuation.

Why Long Term?

The rebalancing of the pipeline indicates a strategic shift that may take time to yield results, paralleling historical pipeline adjustments that have led to eventual market gains.

Related Companies

JNJAMGNABBV
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today reported financial results for the fourth quarter and full year ended December 31, 2024 and provided clinical updates and priorities for 2025. “In 2024, we began rebalancing our pipeline to focus on XmAb® drug candidates that leverage our protein engineering strengths and reduce exposure to biologica.

Related News